Literature DB >> 21783218

Prognosis of patients undergoing hepatectomy for solitary hepatocellular carcinoma originating in the caudate lobe.

Yoshihiro Sakamoto1, Satoshi Nara, Shojiro Hata, Yusuke Yamamoto, Minoru Esaki, Kazuaki Shimada, Tomoo Kosuge.   

Abstract

BACKGROUND: Operative and nonoperative treatment for hepatocellular carcinoma (HCC) originating in the caudate lobe is regarded as challenging because of its deep location in the liver and possibly worse prognosis than HCC in other sites in the liver. The objective of this study is to investigate the clinicopathologic factors and survival of patients who underwent hepatectomy for solitary HCC originating in the caudate lobe.
METHODS: A retrospective review of 783 patients who underwent curative hepatectomy for solitary HCC between 1988 was performed. Clinicopathologic factors and survival rate of 46 (5.9%) patients with HCC originating in the caudate lobe were compared with those of 737 (94%) patients with HCC arising in other sites.
RESULTS: The clinical backgrounds of patients with HCC in the caudate lobe and in other sites were comparable. Hepatectomy for HCC in the caudate lobe was associated with greater operative time and blood loss than for HCC in other sites of the liver. Pathologically, HCC in the caudate lobe was associated with less frequent intrahepatic metastasis, lesser operative margins, and more frequent tumor exposure than HCC in other sites. Overall and disease-free 5-year survival rates of the 46 patients with solitary HCC in the caudate lobe were 76% and 45%, respectively; no significant difference was observed in the overall or disease-free survival rates between the 2 groups (P = .07 and P = .77, respectively). Resection of HCC in the paracaval portion of the caudate lobe (n = 27) was associated with more frequent anatomic resection, greater operative time and blood loss, and a lesser operative margin than HCC in the Spiegel lobe or caudate process (n = 19).
CONCLUSION: Resection for HCC in the caudate lobe, especially in the paracaval portion, remains technically demanding. The prognosis of patients with solitary HCC in the caudate lobe, however, was as good as that of patients with solitary HCC in other sites in the liver.
Copyright © 2011 Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21783218     DOI: 10.1016/j.surg.2011.03.005

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  11 in total

1.  Anterior hepatic parenchymal transection for complete caudate lobectomy to treat liver cancer situated in or involving the paracaval portion of the caudate lobe.

Authors:  Zhen-Guang Wang; WanYee Lau; Si-Yuan Fu; Hui Liu; Ze-Ya Pan; Yuan Yang; Jin Zhang; Meng-Chao Wu; Wei-Ping Zhou
Journal:  J Gastrointest Surg       Date:  2015-03-11       Impact factor: 3.452

2.  Parenchymal-sparing approaches for resection of tumors located in the paracaval portion of the caudate lobe of the liver-utility of limited resection and central hepatectomy.

Authors:  Masaharu Kogure; Yutaka Suzuki; Hirokazu Momose; Ryota Matsuki; Toshiyuki Mori; Kimitaka Kogure; Yoshihiro Sakamoto
Journal:  Langenbecks Arch Surg       Date:  2021-06-01       Impact factor: 3.445

3.  Prognoses and Clinicopathological Characteristics for Hepatocellular Carcinoma Originating from the Caudate Lobe After Surgery.

Authors:  Shingo Shimada; Toshiya Kamiyama; Hideki Yokoo; Tatsuya Orimo; Akihisa Nagatsu; Takanori Ohata; Hirofumi Kamachi; Akinobu Taketomi
Journal:  World J Surg       Date:  2019-04       Impact factor: 3.352

4.  Choice of approach for hepatectomy for hepatocellular carcinoma located in the caudate lobe: isolated or combined lobectomy?

Authors:  Peng Liu; Bao-An Qiu; Gang Bai; Hong-Wei Bai; Nian-Xin Xia; Ying-Xiang Yang; Jian-Yong Zhu; Yang An; Bing Hu
Journal:  World J Gastroenterol       Date:  2012-08-07       Impact factor: 5.742

5.  Laparoscopic liver resection for primary liver cancers originating in the paracaval portion of the caudate lobe: a preliminary retrospective analysis with 31 patients.

Authors:  Tiange Sun; Xiaojun Wang; Li Cao; Jianwei Li; Jian Chen; Xuesong Li; Kexi Liao; Shuguo Zheng
Journal:  Updates Surg       Date:  2021-09-29

6.  Caudate Lobe Hepatocellular Carcinoma Treated with Sequential Transarterial Chemoembolization and Iodine 125 Seeds Implantation: A Single-Center Retrospective Study.

Authors:  Liangliang Yan; Lei Chen; Kun Qian; Xuefeng Kan; Hongsen Zhang; Bin Liang; Chuansheng Zheng
Journal:  Cancer Manag Res       Date:  2021-05-13       Impact factor: 3.989

7.  Long-term clinical outcomes of patients receiving proton beam therapy for caudate lobe hepatocellular carcinoma.

Authors:  Takashi Iizumi; Toshiyuki Okumura; Yuta Sekino; Hiroaki Takahashi; Yu-Lun Tsai; Daichi Takizawa; Toshiki Ishida; Yuichi Hiroshima; Masatoshi Nakamura; Shosei Shimizu; Takashi Saito; Haruko Numajiri; Masashi Mizumoto; Kei Nakai; Hideyuki Sakurai
Journal:  J Radiat Res       Date:  2021-07-10       Impact factor: 2.724

8.  Isolated caudate lobe resection: technical challenges.

Authors:  Sastha Ahanatha Pillai; Jeswanth Sathyanesan; Senthilkumar Perumal; Srinivasan Ulagendra Perumal; Anand Lakshmanan; Sukumar Ramaswami; Ravi Ramasamy; Ravichandran Palaniappan; Surendran Rajagopal
Journal:  Ann Gastroenterol       Date:  2013

9.  Multi-Institutional Retrospective Study of Radiotherapy for Hepatocellular Carcinoma in the Caudate Lobe.

Authors:  Sung Uk Lee; Sang Min Yoon; Jason Chia-Hsien Cheng; Tae Hyun Kim; Bo Hyun Kim; Jin-Hong Park; Jinhong Jung; Chiao-Ling Tsai; Yun Chiang; Joong-Won Park
Journal:  Front Oncol       Date:  2021-02-26       Impact factor: 6.244

10.  Superselective Transarterial Chemoembolization for Unresectable or "Ablation Unsuitable" Hepatocellular Carcinoma in the Caudate Lobe: A Real World, Single-Center Retrospective Study.

Authors:  Liangliang Yan; Yanqiao Ren; Kun Qian; Xuefeng Kan; Hongsen Zhang; Lei Chen; Bin Liang; Chuansheng Zheng
Journal:  Front Oncol       Date:  2021-10-28       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.